Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionlow-density lipoprotein particle receptor activity

LRP1 LRP12 SORL1

4.77e-0716203GO:0005041
GeneOntologyMolecularFunctionlipoprotein particle receptor activity

LRP1 LRP12 SORL1

1.13e-0621203GO:0030228
GeneOntologyMolecularFunctioncargo receptor activity

LRP1 LRP12 SORL1

8.05e-0585203GO:0038024
GeneOntologyBiologicalProcessregulation of cholesterol import

LRP1 LAMTOR1

3.20e-059202GO:0060620
GeneOntologyBiologicalProcessmaintenance of protein location in cell

MORC3 SORL1 TNRC6A

5.24e-0576203GO:0032507
GeneOntologyBiologicalProcessmaintenance of location in cell

MYO5A MORC3 SORL1 TNRC6A

1.00e-04259204GO:0051651
GeneOntologyBiologicalProcesscholesterol import

LRP1 LAMTOR1

1.06e-0416202GO:0070508
GeneOntologyBiologicalProcessmaintenance of protein location

MORC3 SORL1 TNRC6A

1.66e-04112203GO:0045185
GeneOntologyCellularComponentinsulin-responsive compartment

LRP1 MYO5A

4.76e-0511202GO:0032593
DomainLDLR_class-A_CS

LRP1 LRP12 SORL1

7.26e-0640183IPR023415
DomainLdl_recept_a

LRP1 LRP12 SORL1

1.04e-0545183PF00057
Domain-

LRP1 LRP12 SORL1

1.11e-05461834.10.400.10
DomainLDLRA_1

LRP1 LRP12 SORL1

1.27e-0548183PS01209
DomainLDrepeatLR_classA_rpt

LRP1 LRP12 SORL1

1.35e-0549183IPR002172
DomainLDLa

LRP1 LRP12 SORL1

1.35e-0549183SM00192
DomainLDLRA_2

LRP1 LRP12 SORL1

1.35e-0549183PS50068
DomainLdl_recept_b

LRP1 SORL1

7.93e-0514182PF00058
DomainLDLRB

LRP1 SORL1

7.93e-0514182PS51120
DomainLY

LRP1 SORL1

9.14e-0515182SM00135
DomainLDLR_classB_rpt

LRP1 SORL1

9.14e-0515182IPR000033
Domain-

LRP1 SORL1

6.36e-04391822.120.10.30
Domain6-blade_b-propeller_TolB-like

LRP1 SORL1

8.85e-0446182IPR011042
DomainEGF_3

LRP1 NOTCH2 SORL1

1.40e-03235183PS50026
DomainEGF

LRP1 NOTCH2 SORL1

1.40e-03235183SM00181
DomainEGF-like_dom

LRP1 NOTCH2 SORL1

1.65e-03249183IPR000742
DomainEGF-like_CS

LRP1 NOTCH2 SORL1

1.88e-03261183IPR013032
DomainEGF_2

LRP1 NOTCH2 SORL1

1.97e-03265183PS01186
DomainEGF_CA

LRP1 NOTCH2

3.06e-0386182PF07645
DomainEGF_Ca-bd_CS

LRP1 NOTCH2

3.87e-0397182IPR018097
DomainEGF_CA

LRP1 NOTCH2

4.03e-0399182PS01187
DomainASX_HYDROXYL

LRP1 NOTCH2

4.11e-03100182PS00010
DomainEGF-type_Asp/Asn_hydroxyl_site

LRP1 NOTCH2

4.60e-03106182IPR000152
DomainEGF_CA

LRP1 NOTCH2

6.05e-03122182SM00179
DomainEGF-like_Ca-bd_dom

LRP1 NOTCH2

6.24e-03124182IPR001881
DomainEGF

LRP1 NOTCH2

6.44e-03126182PF00008
DomainGrowth_fac_rcpt_

LRP1 NOTCH2

9.71e-03156182IPR009030
Pubmed

Dimerization leads to changes in APP (amyloid precursor protein) trafficking mediated by LRP1 and SorLA.

LRP1 SORL1

9.42e-07320228799085
Pubmed

UBE3A-mediated p18/LAMTOR1 ubiquitination and degradation regulate mTORC1 activity and synaptic plasticity.

UBE3A LAMTOR1

9.42e-07320230020076
Pubmed

The pro-neurotrophin receptor sortilin is a major neuronal apolipoprotein E receptor for catabolism of amyloid-β peptide in the brain.

LRP1 SORL1

1.88e-06420223283348
Pubmed

LRP1 induces anti-PD-1 resistance by modulating the DLL4-NOTCH2-CCL2 axis and redirecting M2-like macrophage polarisation in bladder cancer.

LRP1 NOTCH2

1.88e-06420238462037
Pubmed

Interaction of the apolipoprotein E receptors low density lipoprotein receptor-related protein and sorLA/LR11.

LRP1 SORL1

3.14e-06520219047013
Pubmed

Apolipoprotein A-V interaction with members of the low density lipoprotein receptor gene family.

LRP1 SORL1

3.14e-06520217326667
Pubmed

Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance.

LRP1 SORL1

1.13e-05920220005821
Pubmed

Deficiency of Lipoprotein Lipase in Neurons Decreases AMPA Receptor Phosphorylation and Leads to Neurobehavioral Abnormalities in Mice.

LRP1 SORL1

3.75e-051620226263173
Pubmed

MMS19 assembles iron-sulfur proteins required for DNA metabolism and genomic integrity.

NARF CTU2 DUSP9

8.49e-0515020322678362
Pubmed

Cytoplasmic aggregation of DDX1 in developing embryos: Early embryonic lethality associated with Ddx1 knockout.

BRWD1 TNRC6A

1.26e-042920231330130
Pubmed

Use of comparative physical and sequence mapping to annotate mouse chromosome 16 and human chromosome 21.

MORC3 BRWD1

1.35e-043020211374901
Pubmed

An inducible CRISPR/Cas9 screen identifies DTX2 as a transcriptional regulator of human telomerase.

NOTCH2 LAMTOR1 TNRC6A

1.46e-0418020335198878
Pubmed

Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer.

LRP1 NOTCH2 TNRC6A

1.55e-0418420332908313
Pubmed

Comprehensive identification of phosphorylation sites in postsynaptic density preparations.

MYO5A AJM1 BRWD1

3.03e-0423120316452087
Pubmed

Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity.

LRP1 NOTCH2 SORL1 BRWD1 TNRC6A

3.50e-04111620531753913
Pubmed

K48- and K63-linked ubiquitin chain interactome reveals branch- and length-specific ubiquitin interactors.

UBE3A RFWD3 MORC3 LAMTOR1

3.50e-0460420438803224
Pubmed

Neuron-specific protein network mapping of autism risk genes identifies shared biological mechanisms and disease-relevant pathologies.

COIL MYO5A UBE3A AJM1 TNRC6A

3.84e-04113920536417873
Pubmed

Isolation of human proteasomes and putative proteasome-interacting proteins using a novel affinity chromatography method.

UBE3A MORC3

5.09e-045820219013454
GeneFamilyLow density lipoprotein receptors

LRP1 LRP12

4.32e-0513142634
GeneFamilyWD repeat domain containing

RFWD3 BRWD1

1.70e-02262142362
CoexpressionGSE28737_FOLLICULAR_VS_MARGINAL_ZONE_BCELL_UP

LRP1 LAMTOR1 BRWD1 TNRC6A

1.42e-05199204M9351
CoexpressionGSE21546_UNSTIM_VS_ANTI_CD3_STIM_DP_THYMOCYTES_UP

MYO5A CCNG2 LRP12 MORC3

1.42e-05199204M7548
CoexpressionGSE26343_UNSTIM_VS_LPS_STIM_MACROPHAGE_DN

LRP1 CCNG2 NOTCH2 RFWD3

1.45e-05200204M8648
CoexpressionGSE23502_BM_VS_COLON_TUMOR_MYELOID_DERIVED_SUPPRESSOR_CELL_DN

CCNG2 MORC3 SORL1 BRWD1

1.45e-05200204M8088
CoexpressionRUTELLA_RESPONSE_TO_HGF_DN

CCNG2 NARF NOTCH2 SORL1

2.96e-05240204M6413
CoexpressionCHIANG_LIVER_CANCER_SUBCLASS_UNANNOTATED_UP

MAP3K13 SORL1 TNRC6A

3.73e-0586203M19610
CoexpressionSCHLOSSER_SERUM_RESPONSE_DN

COIL LRP1 CCNG2 UBE3A MORC3

1.54e-04705205M1410
CoexpressionGSE26488_CTRL_VS_PEPTIDE_INJECTION_OT2_THYMOCYTE_DN

LRP12 SORL1 BRWD1

3.50e-04183203M8189
CoexpressionGSE9988_ANTI_TREM1_VS_VEHICLE_TREATED_MONOCYTES_DN

CCNG2 SORL1 TNRC6A

4.34e-04197203M5853
CoexpressionGSE17721_CTRL_VS_PAM3CSK4_2H_BMDC_UP

NARF RFWD3 LAMTOR1

4.47e-04199203M3733
CoexpressionGSE32986_CURDLAN_HIGHDOSE_VS_GMCSF_AND_CURDLAN_HIGHDOSE_STIM_DC_UP

CCNG2 RFWD3 SORL1

4.47e-04199203M8636
CoexpressionGSE360_CTRL_VS_L_DONOVANI_DC_UP

COIL LRP1 SORL1

4.47e-04199203M5143
CoexpressionGSE12392_IFNAR_KO_VS_IFNB_KO_CD8_NEG_SPLEEN_DC_UP

CCNG2 LRP12 BRWD1

4.47e-04199203M7142
CoexpressionGSE22886_DAY0_VS_DAY7_MONOCYTE_IN_CULTURE_UP

CCNG2 NOTCH2 SORL1

4.47e-04199203M4460
CoexpressionGSE28237_FOLLICULAR_VS_LATE_GC_BCELL_UP

AJM1 BRWD1 TNRC6A

4.47e-04199203M4886
CoexpressionGSE33162_HDAC3_KO_VS_HDAC3_KO_4H_LPS_STIM_MACROPHAGE_UP

NOTCH2 LAMTOR1 SORL1

4.53e-04200203M9041
CoexpressionGSE27859_CD11C_INT_F480_HI_MACROPHAGE_VS_CD11C_ING_F480_INT_DC_DN

LRP1 CCNG2 SORL1

4.53e-04200203M8598
CoexpressionGSE29618_MONOCYTE_VS_MDC_UP

LRP1 NOTCH2 SORL1

4.53e-04200203M4948
CoexpressionGSE23502_WT_VS_HDC_KO_MYELOID_DERIVED_SUPPRESSOR_CELL_BM_UP

NOTCH2 SORL1 BRWD1

4.53e-04200203M8090
CoexpressionGSE2585_AIRE_KO_VS_WT_CD80_LOW_MTEC_DN

LRP1 LRP12 LAMTOR1

4.53e-04200203M6270
CoexpressionGSE17721_12H_VS_24H_LPS_BMDC_UP

CCNG2 MORC3 DUSP9

4.53e-04200203M4081
CoexpressionGSE17721_POLYIC_VS_CPG_6H_BMDC_UP

MORC3 LAMTOR1 TNRC6A

4.53e-04200203M3943
CoexpressionGSE17721_LPS_VS_GARDIQUIMOD_2H_BMDC_DN

UBE3A MORC3 LAMTOR1

4.53e-04200203M4044
CoexpressionGSE22886_IGM_MEMORY_BCELL_VS_BM_PLASMA_CELL_UP

NOTCH2 MORC3 SORL1

4.53e-04200203M4456
CoexpressionGSE22886_IGG_IGA_MEMORY_BCELL_VS_BM_PLASMA_CELL_UP

NOTCH2 MORC3 SORL1

4.53e-04200203M4449
CoexpressionAtlasCD positive, CD19 Control, 19+ 4- 8-, Spleen, avg-6

MYO5A NOTCH2 SORL1 BRWD1

2.05e-04339194GSM403988_500
CoexpressionAtlasB cells, B.Fo.Sp, IgD+ IgM+ CD45R+ CD24+ CD19+ AA4.1- CD23+, Spleen, avg-3

MYO5A NOTCH2 SORL1 BRWD1

2.19e-04345194GSM538201_500
CoexpressionAtlasB cells, B.T2.Sp, IgD+ IgM+ CD45R+ CD24+ CD19+ AA4.1+ CD23+, Spleen, avg-3

MYO5A NOTCH2 SORL1 BRWD1

2.26e-04348194GSM538216_500
CoexpressionAtlasB cells, B.Fo.PC, IgD+ IgM+ CD19+ CD43- CD5- CD23+, Peritoneal Cavity, avg-3

MYO5A NOTCH2 SORL1 BRWD1

2.36e-04352194GSM538198_500
CoexpressionAtlasB cells, B.FrF.BM, CD19+ IgM+ AA4.1- HSA+, Bone marrow, avg-3

MYO5A NOTCH2 SORL1 BRWD1

2.77e-04367194GSM399440_500
ToppCellE18.5-Immune-Immune_Myeloid-Monocytic-Macrophage-IM-IM_prolif|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

MYO5A LRP12 RFWD3

4.30e-0515420379ebda35dd1719e157738d7c13e5b8ccc3991f03
ToppCelldroplet-Heart-nan|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LRP1 CCNG2 NOTCH2

5.66e-051692032e5bb6437bc9c614e337c5ffb6f6457cd9fc7f4c
ToppCellPND03-Immune-Immune_Myeloid-Monocytic-Macrophage-AM-AM_mature|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

LRP1 MYO5A LRP12

7.29e-05184203fe9ea4d0e0be820e95eaf9bb42a5560d0e177574
ToppCell367C-Lymphocytic-NK_cells-NK_cell_D3|NK_cells / Donor, Lineage, Cell class and subclass (all cells)

CCNG2 MAP3K13 RFWD3

7.41e-051852034a5e70ac41e5f3b25a773304ffef3c2a3dd5549d
ToppCellMyeloid-B_(Activated_Macrophage)|World / shred on cell class and cell subclass (v4)

LRP1 MYO5A LRP12

7.53e-0518620333d731a7883d75e4e7db83b641cdb1e9a39938bf
ToppCellPND03-Immune-Immune_Myeloid-Monocytic-Macrophage-AM|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

LRP1 MYO5A LRP12

7.53e-051862037950e03ea080238c168b9d807e217f459acdfb28
ToppCellfacs-Spleen-nan-3m-Lymphocytic-CD79a_B_cell|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

NOTCH2 SORL1 BRWD1

7.65e-05187203b51af2824e65734f333b1325117f4a2e88b17c23
ToppCellfacs-Spleen-nan-3m-Lymphocytic-B_cell|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

NOTCH2 SORL1 BRWD1

7.65e-051872033ca3954f45f167e98a230f2847f0582d74fcd32e
ToppCellAdult-Immune-alveolar_macrophage_(MARCO_positive)-D175|Adult / Lineage, Cell type, age group and donor

LRP1 MYO5A LRP12

8.27e-05192203733491e932350e3c216a626cc49c3cd3fe970a82
ToppCellfacs-Heart-RA-3m-Mesenchymal-fibroblast_of_cardiac_tissue|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LRP1 CCNG2 NOTCH2

8.53e-051942034f31d2cf7eb37b45fefc4da5b41aac0bfdd847b3
ToppCellfacs-Heart-RA-3m-Mesenchymal-fibroblast_of_cardiac_tissue|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LRP1 CCNG2 NOTCH2

8.53e-0519420348063c9fe3e12aeff0707acada1baa2f8621f093
ToppCellfacs-Heart-RA-3m|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LRP1 CCNG2 NOTCH2

8.92e-05197203940cf1e54d7c820e04946258a8b784f35c6a144c
ToppCellBAL-Severe-Myeloid-TRAM-TRAM2|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

LRP1 LAMTOR1 SORL1

8.92e-0519720333f2fe101ae5744eea3915add37e60aa398bb97f
ToppCellBAL-Severe-Myeloid-TRAM-TRAM2|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)

LRP1 LAMTOR1 SORL1

8.92e-05197203d8ef5cb88dd66e112cb94217b9ad5cd70164f1d0
ToppCellBAL-Severe-Myeloid-TRAM-TRAM2-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

LRP1 LAMTOR1 SORL1

8.92e-051972039262785807faeb32417fad7ef202405053e453e2
ToppCellBAL-Severe-Myeloid-TRAM-TRAM2-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

LRP1 LAMTOR1 SORL1

8.92e-051972035e9a3932ae5147a3d73dc70f1545926a692930ed
ToppCellSevere_COVID-19-Myeloid-TRAM2|Severe_COVID-19 / Disease group,lineage and cell class （2021.01.30）

LRP1 LAMTOR1 SORL1

8.92e-051972038a126cfe1529f3d75a806aa492743314a8a43ef9
ToppCellSevere_COVID-19-Myeloid-MoAM4|Severe_COVID-19 / Disease group,lineage and cell class （2021.01.30）

LRP1 MYO5A LRP12

9.33e-0520020330448a41ca64d6f0fedaff0b7a6670dd33cdf2c5
ToppCellBAL-Severe-Myeloid-MoAM-MoAM4|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

LRP1 MYO5A LRP12

9.33e-05200203cf720d3973e79ffd4c6e763a7284799ced22a274
ToppCellBAL-Severe-Myeloid-MoAM-MoAM4|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)

LRP1 MYO5A LRP12

9.33e-05200203df821ac12953e44fcfedbbefb35a4976e406ccd6
ToppCellBAL-Severe-Myeloid-MoAM-MoAM4-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

LRP1 MYO5A LRP12

9.33e-052002034f481d87e30195365900acb5d50641a9e7b2f462
ToppCellBAL-Severe-Myeloid-MoAM-MoAM4-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

LRP1 MYO5A LRP12

9.33e-052002035490393c5f54748f912676e19b58bd1320415a06
ToppCellMS-IIF-Lymphocyte-T/NK-dn_T|IIF / Disease, condition lineage and cell class

CCNG2 UBE3A BRWD1

9.33e-05200203c34fff02992cba6bcc2308019cb00b94e1227300
Drugmonatepil

LRP1 LRP12 SORL1

1.78e-0629193CID000060810
DrugN,N-dibenzylphenylethanolamine

LRP1 LRP12

3.95e-064192CID000048896
Drug25-hydroxycholesterol

LRP1 LRP12 NOTCH2 SORL1

8.39e-06160194CID000065094
DrugPicotamide monohydrate [80530-63-8]; Down 200; 10.2uM; PC3; HT_HG-U133A

CCNG2 LRP12 NOTCH2 BRWD1

1.90e-051971942070_DN
Drugpitavastatin

LRP1 LRP12 SORL1

1.12e-04114193CID005282451
DrugAC1L2GOW

LRP1 LRP12

1.24e-0420192CID000046762
DrugAC1MTXUO

LRP1 LRP12

1.51e-0422192CID003632206
Drugcholesteryl ether

LRP1 LRP12

1.80e-0424192CID000296867
Drugezetimibe

LRP1 LRP12 SORL1

2.37e-04147193CID000150311
Drugtetrahydroaldosterone-3-glucuronide

LRP1 LRP12

2.64e-0429192CID000167918
Drugprobucol

LRP1 LRP12 SORL1

3.15e-04162193CID000004912
DrugNocodazole [31430-18-9]; Up 200; 13.2uM; HL60; HG-U133A

CCNG2 LRP12 MORC3

4.02e-041761931393_UP
Drugradicicol, diheterospora chlamydosporia; Up 200; 0.1uM; HL60; HT_HG-U133A

CCNG2 LRP12 MORC3

4.08e-041771932679_UP
DrugAdamantamine fumarate [80789-67-9]; Down 200; 9.6uM; HL60; HT_HG-U133A

CCNG2 LRP12 BRWD1

4.57e-041841931344_DN
DrugHydrocotarnine hydrobromide [5985-00-2]; Down 200; 13.2uM; HL60; HG-U133A

CCNG2 NARF LRP12

4.57e-041841931772_DN
DrugApigenin [520-36-5]; Down 200; 14.8uM; PC3; HT_HG-U133A

CCNG2 LRP12 NOTCH2

4.72e-041861934578_DN
DrugMyricetin [529-44-2]; Up 200; 12.6uM; HL60; HT_HG-U133A

LRP12 NOTCH2 BRWD1

4.72e-041861931334_UP
DrugPerphenazine [58-39-9]; Up 200; 10uM; MCF7; HT_HG-U133A

CCNG2 LRP12 MAP3K13

4.80e-041871935698_UP
DrugSyrosingopine [84-36-6]; Up 200; 6uM; PC3; HT_HG-U133A

CCNG2 UBE3A MAP3K13

4.87e-041881935733_UP
Drugpioglitazone HCl; Down 200; 10uM; PC3; HT_HG-U133A

LRP1 CCNG2 BRWD1

5.02e-041901937528_DN
DrugSanguinarine [2447-54-3]; Down 200; 12uM; MCF7; HT_HG-U133A

NOTCH2 SORL1 BRWD1

5.10e-041911934168_DN
DrugAC1NAL8H

LRP1 LRP12

5.31e-0441192CID004478772
DrugPridinol methanesulfonate salt [6856-31-1]; Down 200; 10.2uM; MCF7; HT_HG-U133A

LRP12 NOTCH2 MORC3

5.34e-041941937214_DN
DrugResveratrol [501-36-0]; Down 200; 17.6uM; HL60; HG-U133A

CCNG2 MORC3 SORL1

5.34e-041941931715_DN
DrugSulfaphenazole [526-08-9]; Down 200; 12.8uM; HL60; HT_HG-U133A

CCNG2 LRP12 BRWD1

5.42e-041951931836_DN
DrugSC-560; Up 200; 10uM; MCF7; HT_HG-U133A

CCNG2 MORC3 BRWD1

5.42e-041951936913_UP
Drugwortmannin from Penicillium funiculosum; Up 200; 0.01uM; PC3; HT_HG-U133A

LRP1 CCNG2 MAP3K13

5.42e-041951934467_UP
DrugOrnidazole [16773-42-5]; Down 200; 18.2uM; HL60; HG-U133A

CCNG2 NOTCH2 MORC3

5.50e-041961931425_DN
DrugMetronidazole [443-48-1]; Down 200; 23.4uM; PC3; HG-U133A

CCNG2 UBE3A LRP12

5.50e-041961931921_DN
DrugBenzamil hydrochloride [2898-76-2]; Up 200; 11.2uM; PC3; HT_HG-U133A

CCNG2 LRP12 MAP3K13

5.50e-041961934294_UP
DrugChlorphensin carbamate [886-74-8]; Down 200; 16.2uM; HL60; HG-U133A

MYO5A UBE3A MORC3

5.50e-041961931432_DN
DrugTolnaftate [2398-96-1]; Up 200; 13uM; MCF7; HT_HG-U133A

CCNG2 LRP12 NOTCH2

5.50e-041961934805_UP
DrugEnoxacin [74011-58-8]; Up 200; 12.4uM; HL60; HG-U133A

UBE3A LRP12 MORC3

5.58e-041971931597_UP
DrugLevamisole hydrochloride [16595-80-5]; Down 200; 16.6uM; HL60; HG-U133A

CCNG2 UBE3A MORC3

5.58e-041971931410_DN
DrugYohimbine hydrochloride [65-19-0]; Down 200; 10.2uM; PC3; HT_HG-U133A

CCNG2 UBE3A BRWD1

5.58e-041971937130_DN
DrugZimelidine dihydrochloride monohydrate [61129-30-4]; Down 200; 9.8uM; PC3; HG-U133A

UBE3A LRP12 MORC3

5.58e-041971931930_DN
DrugIndoprofen [31842-01-0]; Up 200; 14.2uM; HL60; HT_HG-U133A

LRP1 UBE3A NOTCH2

5.58e-041971933007_UP
Drug3-Acetamidocoumarin [779-30-6]; Up 200; 19.6uM; PC3; HT_HG-U133A

NOTCH2 MAP3K13 BRWD1

5.66e-041981934601_UP
DrugGSK-3 Inhibitor IX; Down 200; 0.5uM; PC3; HT_HG-U133A

CCNG2 NOTCH2 BRWD1

5.66e-041981936559_DN
DrugAlprenolol hydrochloride [13707-88-5]; Down 200; 14uM; HL60; HG-U133A

CCNG2 LRP12 RFWD3

5.66e-041981931571_DN
Drug5255229; Down 200; 13uM; MCF7; HT_HG-U133A_EA

UBE3A SORL1 BRWD1

5.66e-04198193833_DN
DrugTriamterene [396-01-0]; Up 200; 15.8uM; PC3; HT_HG-U133A

LRP1 CCNG2 MAP3K13

5.66e-041981937307_UP
DrugNaringin hydrate [11032-30-7]; Down 200; 6.6uM; HL60; HT_HG-U133A

CCNG2 NOTCH2 SORL1

5.66e-041981932425_DN
DrugPF-00562151-00 [351320-12-2]; Up 200; 10uM; PC3; HT_HG-U133A

CCNG2 NOTCH2 BRWD1

5.66e-041981936907_UP
DrugMeclofenamic acid sodium salt monohydrate [6385-02-0]; Up 200; 11.8uM; PC3; HT_HG-U133A

LRP1 LRP12 BRWD1

5.66e-041981937280_UP
DrugTiclopidine hydrochloride [53885-35-1]; Down 200; 13.4uM; PC3; HT_HG-U133A

LRP12 NOTCH2 BRWD1

5.66e-041981934074_DN
DrugSuramin sodium salt; Down 200; 10uM; MCF7; HT_HG-U133A

CCNG2 MORC3 BRWD1

5.75e-041991937524_DN
DrugPractolol [6673-35-4]; Down 200; 15uM; PC3; HT_HG-U133A

CCNG2 NOTCH2 BRWD1

5.75e-041991934603_DN
DrugIvermectin [70288-86-7]; Up 200; 4.6uM; PC3; HT_HG-U133A

CCNG2 NOTCH2 BRWD1

5.75e-041991935853_UP
DrugHomosalate [118-56-9]; Up 200; 15.2uM; PC3; HT_HG-U133A

LRP1 UBE3A MAP3K13

5.75e-041991934533_UP
DrugLevocabastine hydrochloride [79547-78-7]; Up 200; 8.8uM; PC3; HT_HG-U133A

LRP1 UBE3A BRWD1

5.75e-041991937249_UP
DrugDibucaine [85-79-0]; Down 200; 11.6uM; PC3; HG-U133A

CCNG2 LRP12 MORC3

5.75e-041991931889_DN
Drugovothiol A

LRP1 LRP12

6.11e-0444192CID000130131
DiseaseNeoplasm Invasiveness

CTU2 NOTCH2 SORL1

1.82e-04184183C0027626
DiseaseBreast adenocarcinoma

NOTCH2 MAP3K13

2.84e-0441182C0858252
DiseaseNeoplasm of uncertain or unknown behavior of breast

NOTCH2 MAP3K13

2.84e-0441182C0496956
Diseasehepatocyte growth factor measurement

NOTCH2 BRWD1

3.27e-0444182EFO_0006903
Diseasealcohol use disorder measurement, alcohol consumption measurement

SORL1 TNRC6A

1.58e-0397182EFO_0007878, EFO_0009458
DiseaseAlzheimer's disease (is_implicated_in)

LRP1 SORL1

2.90e-03132182DOID:10652 (is_implicated_in)
Diseasebitter alcoholic beverage consumption measurement

SORL1 TNRC6A

2.94e-03133182EFO_0010092
DiseaseMalignant neoplasm of breast

CTU2 NOTCH2 MAP3K13 SORL1

3.55e-031074184C0006142
DiseaseBreast Carcinoma

CTU2 NOTCH2 MAP3K13

4.01e-03538183C0678222
Diseaseepilepsy (implicated_via_orthology)

LRP1 UBE3A

4.38e-03163182DOID:1826 (implicated_via_orthology)

Protein segments in the cluster

PeptideGeneStartEntry
HKEDEAMSCSENCSS

APLF

316

Q8IW19
SADEDDLMTCSNARC

AJM1

656

C9J069
ESESEDSCEDMSCGE

CCNG2

301

Q16589
DSCEDMSCGEESLSS

CCNG2

306

Q16589
SASMDEEEGDTCTIC

RFWD3

276

Q6PCD5
DCTEDVDECAMANSN

NOTCH2

411

Q04721
NNMDECGDSSDEEIC

LRP12

186

Q9Y561
RCDGDTDCMDSSDEK

LRP1

1081

Q07954
TDCMDSSDEKSCEGV

LRP1

1086

Q07954
QFVDCEDASDEMNCS

LRP1

2626

Q07954
EDASDEMNCSATDCS

LRP1

2631

Q07954
ECSQCSNNESKSEMD

MORC3

796

Q14149
SSDSSAESDDQCLMS

COIL

316

P38432
CSDAESEADRDSMSC

DUSP9

171

Q99956
MQFEESDCDSSDGEC

MAP3K13

936

O43283
MSQCSSDHGCETDLD

BRWD1

1856

Q9NSI6
MGCCYSSENEDSDQD

LAMTOR1

1

Q6IAA8
CMCALDVDAADSATA

CTU2

391

Q2VPK5
DMDCSLFESCHETSE

MDFIC2

161

A0A1B0GVS7
EDDCGDNSDESHCEM

SORL1

1141

Q92673
AACSAAAMEEDSEAS

UBE3A

196

Q05086
SECMDADSASSSESE

TNRC6A

251

Q8NDV7
SDCLACDSCMTAEEG

NARF

51

Q9UHQ1
DDDAEAICSMCNALT

MYO5A

1761

Q9Y4I1